Glenmark Pharmaceutical Ltd - Stock recommendation by stock market trends

Glenmark Pharmaceuticals Ltd is a worldwide exploration driven drug organization with presence across generics, Specialty and OTC business with activities in more than 80 nations. Company has a promoter holding of 46.65% . Company got final USFDA nod for Lacosamide tablet recently. Stock price raised 2 percent accordingly.

Glenmark Pharmaceuticals Ltd, consolidated in the year 1977, is a Mid Cap organization working in the pharmaceutical sector. For the quarter finished 31.12.2021, the organization has revealed a Consolidated Total Income of Rs. 3187.31 crore, up 1.69 percent from last quarter's all-out pay of Rs. 3134.38 and up 13.76 percent from last year's equivalent quarter complete income of Rs. 2801.85 crore. The organization has announced a net profit after tax of Rs. 239.75 crore in the most recent quarter. It has a decent PE ratio of 11.6. ROE value of the stock is 14.3 percent and ROCE is 14.9% , which indicates the company is almost debt free. The intrinsic value of the company is Rs.507 , A fair price for buy.

Glenmark Pharmaceuticals Ltd has an average target of Rs. 565 within 1 year by 21 analysts with a low level of Rs. 489. On observing the day chart of the stock the price 457 forming a strong support in stock history. The stock is now trading at a price of Rs.457 . It is recommended to BUY keeping a stoploss at Rs. 412. 

If this content seems interesting to you , stay tuned for more updates from this space and also watch my previous article on stock market trends. Give your suggestions on comment section.